# Ex-CEO Behind Bars, 10x’s Clinical Ambitions, and Pharma’s AI Gambit Page: https://stenobird.com/podcast/touching-base-6714887/ex-ceo-behind-bars-10x-s-clinical-ambitions-and-pharma-s-ai-gambit Text version: https://stenobird.com/podcast/touching-base-6714887/ex-ceo-behind-bars-10x-s-clinical-ambitions-and-pharma-s-ai-gambit.md Podcast: [Touching Base](https://stenobird.com/podcast/touching-base-6714887) Published: 2026-01-30T14:33:06+00:00 Episode link: https://shows.acast.com/touching-base/episodes/ex-ceo-behind-bars-10xs-clinical-ambitions-and-pharmas-ai-ga Audio file: https://sphinx.acast.com/p/open/s/65736d39d32e730012c98919/e/697cc123ebb1ff695f473b17/media.mp3 Processing state: not_requested JSON: https://stenobird.com/v1/public/podcasts/touching-base-6714887/episodes/ex-ceo-behind-bars-10x-s-clinical-ambitions-and-pharma-s-ai-gambit Duration seconds: 2057 ## Resource We kick off the very first episode of 2026 with a major legal development. This week, the former CEO of CytoDyn was sentenced to 30 months in prison, more than a year after being convicted on multiple charges including four counts of securities fraud, two counts of wire fraud, and three counts of insider trading. Also, we examine recent investments in artificial intelligence by several major drugmakers, and where they are hoping the technology can make an impact. Then, the latest from 10x Genomics and its plans to expand into clinical diagnostics through new collaboration. And for some research news, a new study that explores how functional forms of amyloid can create stable memories.   Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.  Listed below are links to the GEN stories referenced in this episode of Touching Base :    Ex-CytoDyn CEO Sentenced to 30-Month Prison Term on Fraud, Insider Trading By Alex Philippidis, GEN , January 27, 2026 Pharma Bets Big on AI Platforms with Flurry of New Year Deals By Fay Lin, PhD, GEN Edge , January 22, 2026 JPM: Nvidia Launches AI Collaborations with Eli Lilly, Thermo Fisher By Alex Philippidis, GEN Edge , January 13, 2026 Clinical Ambitions: 10x Expands Beyond Research with Trio of Collaborations By Alex Philippidis, GEN Edge , January 26, 2026 Chai’s the Limit for AI Antibody Designer After $130M Series B Funding By Alex Philippidis, GEN Edge , December 16, 2025 Lilly Expands AI Ties to Insilico, from Customer to Drug Discovery Partner By Alex Philippidis, GEN Edge , November 10, 2025 How Brain May Deliberately Form Amyloids to Turn Experiences Into Memories GEN , January 26, 2026 Touching Base Podcast  … ## Actions - request_transcript: `POST https://stenobird.com/v1/public/podcasts/touching-base-6714887/episodes/ex-ceo-behind-bars-10x-s-clinical-ambitions-and-pharma-s-ai-gambit/transcription-requests` — Idempotently request low-priority transcript generation for this episode. - read_markdown: `GET https://stenobird.com/podcast/touching-base-6714887/ex-ceo-behind-bars-10x-s-clinical-ambitions-and-pharma-s-ai-gambit.md` — Read the agent-friendly Markdown representation of this episode resource. A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed. ## Transcript Full transcripts are not published on public pages unless there is a clear rights basis.